CSIMarket
 
Durect Corp  (DRRX)
Other Ticker:  
 
 
Price: $1.3500 $0.06 4.651%
Day's High: $1.38 Week Perf: 17.39 %
Day's Low: $ 1.27 30 Day Perf: 27.36 %
Volume (M): 107 52 Wk High: $ 7.46
Volume (M$): $ 144 52 Wk Avg: $2.82
Open: $1.27 52 Wk Low: $0.47



 Market Capitalization (Millions $) 37
 Shares Outstanding (Millions) 28
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Durect Corp
Durect Corp is a biopharmaceutical company that specializes in the development of pharmaceutical products using its proprietary drug delivery technologies. The company focuses primarily on developing drugs for the treatment of chronic diseases and conditions, including pain management, neurology, and liver diseases. They utilize various drug delivery systems, such as transdermal patches and injectable implants, to deliver drugs in a controlled and efficient manner. Durect Corp aims to improve the therapeutic benefits and safety profile of existing drugs and develop novel therapies for unmet medical needs.


   Company Address: 10260 Bubb Road Cupertino 95014 CA
   Company Phone Number: 777-1417   Stock Exchange / Ticker: NASDAQ DRRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Durect Corp

Crisis Looms: Durect Corp's Third Quarter Financials Reflect Devastating Revenue Plunge

Durect Corp Discloses Disastrous Q3 2023 Financial Report
Durect Corp, a major pharmaceutical preparations company, recently revealed its financial performance for the third quarter of 2023, which proved to be disastrous. The company experienced a significant decline in revenue, plummeting by -85.439% to $1.74 million compared to the same period in the previous year. Additionally, the net loss per share has increased to $-0.14, a stark contrast to the corresponding financial reporting period a year ago. This reflects a substantial increase from the preceding quarter's net loss per share of $-0.46.
The decline in revenue can be attributed to a reduction of -16.194% from the preceding financial reporting period, where revenue stood at $2.08 million. This significant decrease emphasizes the challenges faced by Durect Corp in a highly competitive pharmaceutical market.

Durect Corp

Durect Corp Reports Stunning Increase in Losses and Unexpected Revenue Growth in Q2 2023

Durect Corp (DRRX) has reported its financial results for the second quarter of 2023, which showed a significant increase in losses compared to the previous year. The company's losses extended to $-0.46 per share, compared to $-0.05 per share a year ago. However, there was an improvement in earnings per share (EPS), which increased from $-0.52 per share in the previous reporting period.
Despite the increase in losses, Durect Corp saw a moderate growth in revenue, with a 0.241% increase to $2.08 million from the same reporting period a year ago. Sequentially, revenue advanced by 1.315% from $2.05 million. This growth in top-line revenue is surprising considering the overall major pharmaceutical preparations industry experienced a 9.44% reduction in revenue.

Durect Corp

Durect Corp's Revenue Rises but Earnings Take a Hit in the First Quarter of 2023

Durect Corp, a pharmaceutical company, has recently released its financial results for the fiscal first quarter of 2023. The company reported a significant increase in its shortfall per share, which stood at $-0.52 per share compared to $-0.05 in the same period last year. Moreover, the shortfall also grew from $-0.05 per share in the preceding reporting period, indicating a significant drop in earnings.
However, there was some positive news for Durect Corp as the revenue for the fiscal first quarter of 2023 advanced by 7.258% to $2.05 million compared to $1.92 million in the corresponding reporting period a year prior. However, the revenue tumbled sequentially by -38.039% from $3.32 million, which could be a cause of concern for investors.






 

Durect's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com